Big Pharma stocks reach record highs amid market shift

Major pharmaceutical companies, including AbbVie, Eli Lilly, and Gilead Sciences, are seeing their stock prices reach or approach record highs. This shift in capital reflects a broader market movement where investors are moving away from high-risk growth stocks in the technology sector toward more stable assets.

Investors are prioritizing companies with stable earnings, robust cash flow, and manageable debt levels. Eli Lilly, in particular, is benefiting from the global surge in demand for GLP-1 receptor agonists used to treat diabetes and obesity, specifically through its products Mounjaro and Zepbound. Demand for these treatments continues to exceed global supply.